Vienna, Austria. 13/10/24: International Bowel Ultrasound Group (IBUS) is creating a new educational program to train the next generation of gastroenterologists, IBD nurse specialists, radiologists and sonographers in intestinal ultrasound (IUS). 


Over the next 3 years, the project will provide comprehensive tools in IUS training to allow wider implementation of this non-invasive, point-of-care technique for the care of patients with inflammatory bowel disease (IBD). The initiative is funded by The Leona M. and Harry B. Helmsley Charitable Trust. 


IBUS has selected Motilent, experts in innovative medical imaging, to provide an eLearning platform. IBUS is dedicated to training gastroenterologists on the highest quality IUS care available to patients with IBD. 


Krisztina Gecse, President of IBUS, says, “The hands-on, Module 2 part of the IBUS curriculum has always been the bottleneck of training and therefore the main barrier for wider adoption of IUS. This initiative will allow IBUS to deliver gold-standard training at a faster pace to more practitioners and therefore will provide access to IUS for more IBD patients globally. Through the new platform, which will complement hands-on sessions, we aim to offer more flexibility, develop early confidence during training, and provide faster implementation of IUS while improving connectivity with the IBUS community. This is an exciting opportunity, and we are looking forward to working together with Motilent on this.” 


Alex Menys, CEO of Motilent, says, “It's been clear for a long time now that IUS has been a vital tool in the armamentarium of clinicians delivering high-quality care to patients. It's non-invasive, cost-effective, and well-tolerated by patients, and we know from trials like METRIC that it works. The problem has always been getting it into the hands of the gastroenterologists so they can sit with their patients and look at treatment response. This can't happen without quality training and standard of care and Motilent is delighted to support this process as this goes forward.”


About IBUS: IBUS is a global non-profit organization, that advances education, research, and clinical applicability of intestinal ultrasound in IBD to ultimately improve patient care with fast tracking management decisions. 


About Motilent: Motilent is on a mission to ensure that the best and most relevant technology is available to benefit patients with digestive disease. Motilent's FDA-listed platform, Entrolytics is the world’s first digestive disease imaging and annotation platform specifically designed for the assessment of digestive diseases, complemented by their quantitative IUS tools to empower clinicians to adopt and deliver the latest advances effectively and safely.


- END -

For further information, please contact:

Beth Fisher | beth.fisher@motilent.io | 

Alex Menys, Motilent CEO, is available for comment. Please email Beth Fisher (above) to arrange.